Supernus Pharma (SUPN) Tops Q2 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq end lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Supernus Announces Second Quarter 2016 Financial Results
August 2, 2016 4:30 PM EDTSecond quarter 2016 product prescriptions totaled 123,758, a 38.9% increase over the second quarter of 2015.Net product sales for second quarter 2016 were $50.3 million, a 46.9% increase over the second quarter of 2015.Operating income for second quarter 2016 was $10.4 million compared to $3.1 million in the second quarter of 2015.   Diluted earnings per share in the second quarter were $0.18 compared to $0.03 in the same period last year.   Enrollment completed in SPN-812 Phase IIb trial. Enrollment for SPN-810 Phase III trials expected to continue into 2017.
ROCKVILLE, Md., Aug. 02, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:... More
